Article Text

Download PDFPDF
PostScript
Correspondence to proton pump inhibitors and risk of colorectal cancer
  1. Chen Dong1,
  2. Yun-Hsun Lee1,
  3. Tzu-Yang Tan1,
  4. Chung-Chin Yao2,
  5. James Cheng-Chung Wei3,4,5,6
  1. 1 School of Medicine, Chung Shan Medical University, Taichung, Taiwan
  2. 2 Division of General Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan
  3. 3 Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan
  4. 4 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
  5. 5 Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
  6. 6 Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
  1. Correspondence to Dr James Cheng-Chung Wei, Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung 402, Taiwan; jccwei{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read with interest the paper by Abrahami et al on the risk of colorectal cancer (CRC) with long-term proton pump inhibitor (PPI) usage with a new user and active comparator design (PPI users n=1 293 749 and histamine-2 receptor antagonist (H2RA) users n=292 387, from 1 January 1990 to 30 April 2018 with 1-year follow-up).1 The authors found that overall use of PPI did not increase the risk of CRC (HR 1.02, 95% CI 0.92 to 1.14). However, the HR increased by 2–4 years (HR 1.45, 95% CI 1.28 to 1.60) and more than 4 years (HR 1.60, 95% CI 1.42 to 1.80) with cumulative duration of PPI usage. Similar patterns were …

View Full Text

Footnotes

  • Contributors CD and Y-HL contribute equally. CD, T-YT and Y-HL draft the manuscript. C-CY and JC-CW revised the manuscript. C-CY and JC-CW are both corresponding authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles